News and reporting on cell-free DNA testing.
The firm said its revenues for the three months ended Dec. 31, 2020 were $78.3 million compared to $62.9 million in the same quarter of 2019.
The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.
The lab will use its phlebotomy network to help Grail with specimen collection for its Galleri multi-cancer early detection blood test, slated to launch this year.
The partners will research the ability of Biocept's Target Selector molecular assay to determine EGFR status in non-small cell lung cancer patients.
The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.
